Assessment of safety on trastuzumab with varied dilution solution volume in HER2 positive breast cancer
Phase 1
Completed
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000034475
- Lead Sponsor
- Kitasato University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1) with severe allergy to trastuzumab 2) Judjed ineligible based on physicians' decision
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate MTD and RD
- Secondary Outcome Measures
Name Time Method serious incidence of infusion reaction after the first treatment with trastuzumab